Docetaxel and cisplatin as first-line chemotherapy in advanced NSCLC.

被引：0
|
作者：
Behera, D [1 ]
Aggarwal, AN [1 ]
Gupta, D [1 ]
Jindal, SK [1 ]
Sharma, SC [1 ]
机构：
[1] Postgrad Inst Med Educ & Res, Chandigarh 160012, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：705S / 705S
页数：1
相关论文
共 50 条
  • [21] Influence of baseline inflammatory markers on the response to first-line chemotherapy in advanced NSCLC
    MacDonald, N.
    Kasymjanova, G.
    Agulnik, J. S.
    Pepe, C.
    Kreisman, H.
    Cohen, V.
    Sharma, R.
    Gagnon, B.
    Small, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 385 - 385
  • [22] A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma
    Chua, DTT
    Sham, JST
    Au, GKH
    ORAL ONCOLOGY, 2005, 41 (06) : 589 - 595
  • [23] DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Ohhara, Y.
    Nishimura, N.
    Nara, E.
    Nakano, K.
    Ueda, K.
    Sakajiri, S.
    Mishima, Y.
    Yokoyama, M.
    Terui, Y.
    Takahashi, S.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 125 - 125
  • [24] Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer
    Kang, Yoon-Koo
    Ryu, Min-Hee
    Yoo, Changhoon
    Chang, Heung-Moon
    Yook, Jeong Hwan
    Oh, Sung Tae
    Kim, Byung Sik
    Kim, Tae Won
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1435 - 1443
  • [25] Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer
    Yoon-Koo Kang
    Min-Hee Ryu
    Changhoon Yoo
    Heung-Moon Chang
    Jeong Hwan Yook
    Sung Tae Oh
    Byung Sik Kim
    Tae Won Kim
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1435 - 1443
  • [26] Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma - A phase II trial
    Baur, M
    Kienzer, HR
    Schweiger, J
    DeSantis, M
    Gerber, E
    Pont, J
    Hudec, M
    Schratter-Sehn, AU
    Wicke, W
    Dittrich, C
    CANCER, 2002, 94 (11) : 2953 - 2958
  • [27] Immunotherapy in the First-Line Setting of Advanced NSCLC
    Herbst, Roy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S107 - S108
  • [28] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
  • [29] A phase 2 study of talabostat/docetaxel in advanced NSCLC.
    Cunningham, C
    Richards, D
    Salgia, R
    Leonard, R
    Raju, R
    Berman, B
    Anthony, S
    Yang, ZJ
    Gregoire, L
    Haltom, E
    Uprichard, MJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9056S - 9057S
  • [30] The integration of docetaxel into first-line chemotherapy for ovarian cancer
    Kaye, SB
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 : 31 - 33
12345